


### Amendments to the Claims

1. (Currently amended) A compound of formula (I):



and pharmaceutically acceptable salts, solvates, ~~chemically protected forms,~~ or and prodrugs thereof, wherein:

$R^6$ ,  $R^7$  and  $R^9$  are independently selected from H, R, OH, OR, SH, SR,  $NH_2$ , NHR, NHRR', nitro,  $Me_3Sn$  and halo;

where R and R' are independently selected from ~~optionally substituted~~  $C_{1-7}$  alkyl,  $C_{3-20}$  heterocyclyl and  $C_{5-20}$  aryl groups;

$R^8$  is selected from H, R, OH, OR, SH, SR,  $NH_2$ , NHR, NHRR', nitro,  $Me_3Sn$  and halo, or the compound is a dimer with each monomer being of formula (I), where the  $R^8$  groups of each monomers form together a dimer bridge having the formula -X- $R''$ -X- linking the monomers, where  $R''$  is a  $C_{3-12}$  alkylene group, which chain may be interrupted by one or more heteroatoms[ $[,]$ ] ~~e.g.~~ selected from the group consisting of O, S, and NH, and/or aromatic rings[ $[,]$ ] ~~e.g.~~ selected from the group consisting of benzene and pyridine, and each X is independently selected from O, S, or NH;

or any pair of adjacent groups from  $R^6$  to  $R^9$  together form a group -O-( $CH_2$ ) $_p$ -O-, where p is 1 or 2; and

$R^2$  is selected from:

- (i) a naphthyl group, optionally substituted by one or more substituents selected from the group consisting of halo,  $C_{1-7}$  alkyl, ether, and  $C_{5-20}$  aryl;
- (ii) a thiophenyl or furanyl group, optionally substituted by one or more substituents selected from the group consisting of halo,  $C_{1-7}$  alkyl, ether, and  $C_{5-20}$  aryl; and
- (iii) a phenyl group substituted by:
  - (a) one or more chloro or fluoro groups;
  - (b) an ethyl or propyl group;
  - (c) a 4-t-butyl group;
  - (d) a 2-methyl group; or
  - (e) two methyl groups in the 2- and 6- positions.

2. (Currently amended) A compound according to claim 1, wherein R<sup>2</sup> is selected from:
- (i) a naphthyl group, optionally substituted by one or more substituents selected from the group consisting of halo, C<sub>1-7</sub> alkyl, ether, and C<sub>5-20</sub> aryl;
  - (ii) a thiophenyl or furanyl group, optionally substituted by one or more substituent selected from the group consisting of halo, C<sub>1-7</sub> alkyl, ether, and C<sub>5-20</sub> aryl; and
  - (iii) a phenyl group substituted by:
    - (a) one or more chloro or fluoro groups;
    - (b) an ethyl or propyl group;
    - (c) a 4-t-butyl group; or
    - (d) a 2-methyl group.
3. (Currently amended) A compound according to claim 2, wherein R<sup>2</sup> is selected from:
- (i) a naphthyl group, optionally substituted by one or more substituent selected from the group consisting of halo, C<sub>1-7</sub> alkyl, ether, and C<sub>5-20</sub> aryl;
  - (ii) a thiophenyl group, optionally substituted by one or more substituent selected from the group consisting of halo, C<sub>1-7</sub> alkyl, ether, and C<sub>5-20</sub> aryl; and
  - (iii) a phenyl group substituted by:
    - (a) one or more chloro or fluoro groups;
    - (b) an ethyl or propyl group;
    - (c) a 4-t-butyl group; or
    - (d) a 2-methyl group.
4. (Previously presented) A compound according to claim 1, wherein R<sup>9</sup> is H.
5. (Previously presented) A compound according to claim 1, wherein R<sup>6</sup> is H.
6. (Previously presented) A compound according to claim 1, wherein R<sup>7</sup> and R<sup>8</sup> (when the compound is not a dimer) are selected from OMe and OCH<sub>2</sub>Ph.
7. (Canceled)

8. (Previously presented) A pharmaceutical composition containing a compound of claim 1, and a pharmaceutically acceptable carrier or diluent.

9. (Canceled)

10. (Currently amended) A method of treatment of melanomas, or breast, renal, or lung cancer, a proliferative disease, comprising administering to a subject in need of treatment a therapeutically-effective amount of a compound of claim 1.